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Background: The effects of intravitreal ranibizumab (IVR) against exudative age-related macular degeneration
(AMD) may be different associated with the lesion phenotype. This study was conducted to compare the outcomes
of IVR between two different phenotypes of exudative AMD: typical neovascular AMD (tAMD) and polypoidal
choroidal vasculopathy (PCV).
Methods: This is a retrospective cohort study of 54 eyes from 54 subfoveal exudative AMD patients (tAMD 24, PCV
30 eyes). Three consecutive IVR treatments (0.5 mg) were performed every month, followed by re-injections as
needed. Change in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were then compared
between the tAMD and PCV groups over 12 months of follow-up.
Results: The mean BCVA was significantly improved (-0.11 logMAR units) at month 3 after the initial IVR (p <0 .001,
Wilcoxon signed-rank test), and was sustained up to 12 months in all AMD patients (p =0.02). In the subgroup
analysis, the tAMD group showed a significant improvement in their mean BCVA (-0.06, -0.17, -0.15 and -0.16
logMAR units at 1, 3, 6 and 12 months, respectively), but there was only a slight but non-significant improvement
in the PCV group. The improvement in the BCVA was significantly greater in the tAMD group than in the PCV
group (p = 0.043, repeated measures ANOVA) over 12 months. Both phenotypes showed significant improvements
in the CRT during 12 months after the initial IVR.
Conclusions: IVR is an effective therapy for tAMD and PCV in the BCVA improvement in Japanese patients over
12 months of follow-up. The phenotype of tAMD showed a significantly better outcome with IVR than PCV in terms
of BCVA improvement.
Keywords: Intravitreal ranibizumab, Polypoidal choroidal vasculopathy, Typical neovascular age-related macular
degeneration, One-year outcome* Correspondence: sighonda@med.kobe-u.ac.jp
Department of Surgery, Division of Ophthalmology, Kobe University
Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017,
Japan
© 2013 Matsumiya et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Matsumiya et al. BMC Ophthalmology 2013, 13:10 Page 2 of 9
http://www.biomedcentral.com/1471-2415/13/10Background
The intravitreal injection of ranibizumab (IVR), an anti-
vascular endothelial growth factor (VEGF) agent, is cur-
rently the choice of treatment for subfoveal choroidal
neovascularization (CNV) due to age-related macular
degeneration (AMD), which is a major cause of irrevers-
ible blindness in the elderly in industrialized countries
[1,2]. Several studies from Western countries have
reported significant improvements in the vision of AMD
patients with predominantly classic, minimally classic
and occult with no classic lesions. Two pivotal phaseIII
clinical studies, the MARINA and ANCHOR studies
[3,4], reported that VA improvements observed with
IVR in the first 3 months were sustained and some
additional improvement was seen over the trial period.
EXTEND-I [5] in Japanese patients with CNV secondary
to AMD also showed the comparable efficacy of IVR
with the MARINA and ANCHOR studies. On the other
hand, since this protocol was often not feasible, a cus-
tomized/individualized pro re nata (PRN) dosing regi-
men of ranibizumab was investigated in order to achieve
optimal VA results with fewer monthly injections. As a
representative study of the PRN use of ranibizumab, the
PrONTO study [6] proposed a flexible dosing regimen
with the OCT and VA- guided criteria for re-treatment.
These visual acuity results were similar to those from
the MARINA and ANCHOR study [7]. However, the ef-
ficacy of IVR has not been well documented for exuda-
tive AMD in the Japanese population. A recent report
described a good response to intravitreous bevacizumab,
an anti-vascular endothelial growth factor (VEGF) anti-
body in off-label use, in Japanese AMD patients with
classic CNV lesions, but there was limited efficacy in
those with occult CNV lesions [8]. Those results might
be attributed to the proportion of AMD subtypes in the
Japanese population, which includes polypoidal chor-
oidal vasculopathy (PCV) as the major phenotype of ex-
udative AMD [9], and the effects of anti-VEGF therapy
for PCV may differ from those for typical neovascular
AMD (tAMD). Recent publications have reported that
the effects of anti- VEGF therapy were limited in PCV
[10,11], but it is not conclusive whether these pheno-
types of AMD are associated with the effectiveness of
IVR or not because there were only a few studies which
conducted direct comparison in the outcomes of IVR
between tAMD and PCV [12,13]. Since IVR is an expen-
sive treatment and carries the risk of complications such
as endophthalmitis, establishing precise indications for
IVR is very important for the best benefit/risk ratio and
cost performance of this therapy. The different effects of
IVR against the different phenotypes may encourage a
better selection of cases eligible for this therapy.
In this study, we first evaluated the efficacy of IVR in
Japanese exudative AMD patients. Next, we performed acomparative assessment to determine whether the ef-
fects of IVR were different between tAMD and PCV in
terms of visual acuity and the number of treatments
over a 12 months follow-up period.
Methods
This is a retrospective interventional cohort study of
consecutive case series with exudative AMD treated by
IVR. All cases in this study were Japanese individuals
recruited from the Department of Ophthalmology at the
Kobe University Hospital in Japan and IVR is a standard
treatment for exudative AMD at the hospital. This study
was approved by the Institutional Review Boards at the
Kobe University Graduate School of Medicine, and was
conducted in accordance with the Declaration of
Helsinki. Written informed consent was obtained from
all subjects.
Fifty-four eyes from 54 subfoveal exudative AMD pa-
tients (tAMD 24, PCV 30 eyes) who underwent the first
IVR between April 2009 and April 2011, with an age
over 50 years and the baseline visual acuity between 20/
25 and 20/320 [14], were followed-up for 12 months. All
patients received detailed ophthalmic examinations, in-
cluding best-corrected visual acuity (BCVA) measure-
ments, slit lamp biomicroscopy of their fundi, color
fundus photography, fluorescein angiography (FA),
indocyanine green angiography (ICGA) and optical co-
herence tomography (OCT). A detailed questionnaire on
the patient’s basic characteristics including age, body
weight and height, the presence or absence of hyperten-
sion and diabetic mellitus, and any history of smoking
(current, past or non-smoker) was also obtained. The
differential diagnoses of tAMD versus PCV were made
in accordance with previous reports [15-17]. Briefly, the
tAMD group included only exudative AMD with clear
images of the vascular CNV networks on ICGA. In the
present study, tAMD included both of classic CNV (15
eyes) and occult CNV (9 eyes), but not RAP lesion in ac-
cordance with the previous report [9]. The PCV cases in
the present study showed subretinal reddish-orange
protrusions corresponding to the choroidal origin of the
polypoidal lesions, typically with the vascular networks
in the posterior poles on ICGA [18,19]. Patients with
past histories of retinal vessel occlusion, uveitis,
rhegmatogenous retinal detachment or glaucoma were
excluded. Patients who received previous photo-
dynamic therapy (PDT) more than 3 months before
IVR were included in the primary analysis to evaluate
the effect of history of PDT.
In the present study, an intravitreal injection of 0.5 mg
of ranibizumab in 0.05 ml was performed per treatment.
All patients received 3 consecutive monthly IVRs, and
were followed-up monthly for 12 months from the initial
IVR in accordance with the PrONTO study criteria [6].
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when sustained or recurrent serous retinal detachment,
macular edema or hemorrhage was recognized by
funduscopy or OCT. The FA and ICGA were repeated
to evaluate the activities of the AMD lesions according
to clinical recommendations if the funduscopic examina-
tions could not explain the recent or progressive VA
deterioration [7].
For statistical analysis, we first compared the gender,
age, BCVA, greatest linear dimension (GLD), central ret-
inal thickness (CRT), history of smoking and previous
PDT therapy, presence of subretinal hemorrhage, serous
retinal detachment, macular edema, retinal pigment epi-
thelial detachment, subretinal fibrosis, hypertension and
diabetes mellitus, and body mass index (BMI) at baseline
between the tAMD and PCV groups. Changes in the
BCVA and CRT were then compared within and be-
tween the tAMD and PCV groups until 12 months after
the initial IVR. The visual acuities were determined
using a Landolt C chart, and were converted to a loga-
rithm of the minimum angle of resolution (logMAR)
values for calculation. The CRT was obtained by OCT
using the central 1 mm of the retinal thickness map with
the Macular cube 200 × 200 scanning protocol (Cirrus
HD OCT, Carl Zeiss Meditec, Dublin, CA). To evaluate
the factors useful for predicting those patients whose
BCVA at 12 months after the initial IVR were improved
over the baseline BCVA, multivariate logistic regression
analyses were performed using explanatory variables
including gender, age, baseline BCVA, baseline GLD,
baseline CRT, the number of previous PDT, history of
smoking, presence of hypertension and diabetes mellitus,
BMI and lesion phenotype (tAMD or PCV). Each vari-
able was first calculated by a univariate logistic model,
then the variables that showed some trend toward sig-
nificant association (P value < 0.2) were further analyzed
by a multivariate logistic model with stepwise method.
All statistical analyses were performed by MedCalc v.11.3
software (MedCalc Software, Mariakerke, Belgium). The
chi-square test, paired t-test, unpaired t-test, Wilcoxon
signed rank test or Mann-Whitney U test, whichever was
the most appropriate, was performed to compare any two
groups. A repeated measures analysis of variance (ANOVA)
was used to make comparisons of changes in the BCVA
between the tAMD and PCV groups over 12 months. P
values of 0.05 or less were considered to be statistically
significant.
Results
The data summary for each phenotype (tAMD and
PCV) is shown in Table 1. None of the pre-treatment
parameters were significantly different between any
groups, except for a significantly larger GLD in the PCV
group than in the tAMD group. In the time courseanalysis, the BCVA at 3 month after the initial IVR was
significantly improved as compared with the baseline
BCVA, and it was sustained for over 12 months in all
AMD subjects (Table 2). In the subgroup analysis, the
tAMD group showed a significant improvement in their
mean BCVA compared to baseline (-0.06, -0.17, -0.15
and -0.16 logMAR units at 1, 3, 6 and 12 months, re-
spectively) (Figure 1 and Table 2). In contrast, in the
PCV group, the BCVA tended to improve over baseline
(0.00, -0.06, -0.06 and -0.04 logMAR units at 1, 3, 6 and
12 months, respectively), but there was no statistical sig-
nificance (Figure 1 and Table 2). A repeated measures
ANOVA revealed a significantly better improvement of
the BCVA in the tAMD group than in the PCV group at
over 12 months (p = 0.043). In addition, the amplitude of
the BCVA improvement was compared between tAMD
and PCV at each time-point measured, which showed
that tAMD achieved a significantly greater visual im-
provement than PCV at 3 M after the initial treatment
(p = 0.43 at 1 M, p = 0.036 at 3 M, p = 0.066 at 6 M and
p = 0.11 at 12 M). To exclude a possible influence of
previous treatment by PDT, we evaluated the visual out-
come of IVR for 16 tAMD patients and 18 PCV patients
who were treatment naïve. In this analysis, the mean
BCVA were significantly improved over baseline in
tAMD group (-0.07, -0.18, -0.17 and -0.14 logMAR units
at 1, 3, 6 and 12 months, p = 0.055, 0.001, 0.008 and
0.049, respectively; Wilcoxon signed rank test), although
PCV group showed modest and non-significant im-
provement in their mean BCVA over 12 months of
follow-up (-0.02, -0.08, -0.07 and -0.07 logMAR units at
1, 3, 6 and 12 months, p = 0.31, 0.07, 0.07 and 0.23, re-
spectively). The time course of the mean CRT in the
tAMD and PCV groups is shown in Figure 2 and Table 2.
Both phenotypes showed significant improvements in
the CRT over 12 months after the initial IVR. There
were no significant differences in the improvements of
the CRT in the tAMD versus the PCV group. The num-
ber of re-treatments after the initial 3 consecutive injec-
tions was 0.9 ± 0.9 (mean ± SD) in the tAMD group, and
1.2 ± 1.3 in the PCV group, which was not significantly
different (p = 0.32, unpaired t-test)
The results of the stepwise logistic regression analyses
are shown in Table 3. The lesion phenotype (tAMD vs.
PCV) was an independent prognostic factor significantly
associated with the improvement in the BCVA at 12
months after the initial IVR, which was actually better in
the tAMD group than in the PCV group.
No ocular or systemic complications were detected
during the follow-up in the present study.
Discussion
We investigated the 12 month outcomes of IVR in
Japanese AMD patients, and investigated whether the
Table 1 Summary of the participants stratified by AMD phenotype
tAMD (n = 24) PCV (n = 30) Total (n = 54) P value
Eye (right eye%) 6 (25%) 13 (43%) 19 (35%) 0.26✝
Gender (males%) 18 (75%) 21 (70%) 39 (72%) 0.92✝
Age, Mean (±SD) (years) 73.2 (±8.5) 76.0 (±7.6) 74.7 (±8.1) 0.21*
Baseline Vision LogMAR (±SD) 0.60 (±0.28) 0.47 (±0.26) 0.53 (±0.28) 0.09*
Baseline macular thickness (±SD) (μm) 392 (±141) 352 (±119) 369 (±129) 0.27*
Baseline GLD (±SD) (μm) 3610 (±962) 4650 (±1665) 4188 (±1480) <0.01*
BMI (±SD) 22.6 (±4.0) 22.1 (±2.8) 22.4 (±3.4) 0.62*
Present or ever-smoking 17 (71%) 20 (67%) 37 (69%) 0.97✝
Hypertension 11 (46%) 13 (43%) 24 (44%) 0.92✝
Diabetic mellitus 5 (21%) 5 (17%) 10 (19%) 0.97✝
Previous PDT therapy 0.40✝
0 16 (67%) 18 (60%) 34 (63%)
1 5 (21%) 4 (13%) 9 (17%)
2≦ 3 (12%) 8 (27%) 11 (20%)
Subretinal hemorrhage (>1DA) 4 (17%) 8 (27%) 12 (22%) 0.58✝
Serous retinal detachment 18 (75%) 26 (87%) 44 (81%) 0.46✝
Macular edema 11 (46%) 12 (40%) 23 (43%) 0.88✝
Retinal pigmented epithelium detachment 21 (88%) 30 (100%) 51 (94%) 0.16✝
Subretinal fibrosis 7 (29%) 4 (13%) 11 (20%) 0.27✝





















Table 2 Changes in the BCVA and CRT from baseline after IVR treatment in all AMD, tAMD and PCV patients
1 Month P value* 3 Months P value* 6 Months P value* 12 Months P value*
Change in BCVA Mean Median (IQR) Mean Median (IQR) Mean Median (IQR) Mean Median (IQR)
total −0.03 0.00 (-0.12 - 0.00) 0.12 −0.11 −0.12 ( -0.24 - 0.00) <0.001 −0.10 −0.12 ( -0.24 - 0.00) 0.001 −0.09 −0.12 (-0.30 - 0.00) 0.02
tAMD −0.06 0.00 (-0.17 - 0.00) 0.01 −0.17 −0.20 (-0.30 - -0.05) <0.001 −0.15 −0.18 (-0.30 - -0.05) 0.006 −0.16 −0.18 (-0.30 - -0.05) 0.01
PCV 0.00 0.00 (-0.10 - 0.00) 0.73 −0.06 −0.07(-0.22 - 0.00) 0.08 −0.06 −0.04 (-0.18 - 0.00) 0.08 −0.04 −0.05 (-0.24 - 0.10) 0.33
Change in CRT Mean Median (IQR) Mean Median (IQR) Mean Median (IQR) Mean Median (IQR)
total −104 −74 (-142 - -25) < 0.001 −132 −119 (-170 - -47) < 0.001 −95 −53 (-126 - -28) < 0.001 −94 −80 (-140 - -40) < 0.001
tAMD −112 −72 (-147 - -29) < 0.001 −144 −93 (-191 - -72) < 0.001 −120 −52 (-154 - -32) < 0.001 −137 −97 (-197 - -52) < 0.001
PCV −98 −107 (-142 - -25) < 0.001 −121 −128 (-170 - -45) < 0.001 −74 −55 (-119 - -28) < 0.001 −94 −71 (-133 - -33) < 0.001
BCVA, Best corrected visual acuity (LogMAR); CRT, Central retinal thickness; IQR, Interquartile range.





















Figure 1 Changes in the best corrected visual acuity (BCVA) for tAMD and PCV patients after intravitreal ranibizumab. The BCVA was
determined using the Landolt C chart, and was presented as decimal visual acuities. Diamonds with solid lines: tAMD; Squares with dashed lines:
PCV. Values represent means ± SEM.
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visual outcomes of IVR. Our results demonstrated that
IVR improved the mean BCVA of exudative AMD in the
Japanese population, and the visual improvement was
significantly greater in the tAMD subjects than in the
PCV subjects. The phenotype of exudative AMD was a
possible significant prognostic factor for the visual acuity
after IVR.
Currently, IVR is the leading therapy for exudative
AMD since the ANCHOR study demonstrated signifi-
cantly better visual outcomes with monthly IVR than
PDT in exudative AMD patients (most of them were
likely tAMD patients) in Western countries [20,21].
However, in Japanese exudative AMD, which likely in-
cludes a number of PCV patients, IVR may not show asFigure 2 Changes in central retinal thickness (CRT) for tAMD and PCV
tAMD; Squares with dashed lines: PCV. Values represent means ± SEM.good an outcome as in Caucasian subjects [8,9,22]. In
the present study, the mean and median LogMAR visual
acuity of all AMD were significantly improved by -0.09
and -0.12 logMAR units at 12 months post-initial IVR,
respectively. This result was compatible to the SUSTAIN
study [23] and a previous report [24], but lower than the
PrONTO and CATT study. In addition, our results
showed a significant increase in the mean BCVA in pa-
tients with tAMD, and a modest improvement in those
with PCV. On the other hand, Song et al. [25] reported
that IVR without PDT for PCV in Korean patients
resulted in visual and anatomical significant improve-
ments over a 1-year follow-up period.
PCV is known to have different characteristics as com-
pared with tAMD, such as orange-red protrusions at thepatients after intravitreal ranibizumab. Diamonds with solid lines:
Table 3 Results of stepwise logistic regression analyses of
preoperative variables associated with an vision gainer
(improvement in the BCVA >0 LogMAR units from the
baseline) at 12 months after the initial IVR
Variable OR 95% CI P value
BMI 1.3 1.0 - 1.6 0.031
Phenotype (PCV = 0, tAMD =1) 4.3 1.2 - 15.9 0.029
OR, Odds ratio; CI, Confidence interval; BMI, Body mass index.
The number of vision gainer and non-gainer was 34 and 20.
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choroidal vascular abnormalities, including vascular
networks of choroidal origin with polypoidal lesions at
their border visualized by ICG [16,18]. In addition,
Nakashizuka et al. [26] suggested that the histopatho-
logic characteristic of PCV was hyalinization of the
choroidal vessels like arteriosclerosis, which is different
from the CNV associated with tAMD. Since PCV ac-
counts for 54.7% of patients with neovascular AMD in
the Japanese population [15] and 22.3% in the Chinese
population [27], it is important to determine if there are
some differences in the efficacy of anti-VEGF therapy
against PCV and tAMD to choose the correct interven-
tion for neovascular AMD in Asian populations.
It was interesting that the PCV patients showed
poorer improvements in their BCVA than tAMD pa-
tients, although both phenotypes showed similar and
significant improvements in their CRT during the 12
months after the initial IVR. A previous report showed
a decrease in macular edema after three monthly
bevacizumab injections in PCV cases [28]. Similarly, the
macular edema evaluated by the CRT measurements
was improved in four out of five eyes with PCV (80%) in
the PEARL study. However, the improvement in the
BCVA was less than that in the ANCHOR or MARINA
trials, although the reasons are unknown [29]. We hy-
pothesized that there might be factors other than macu-
lar edema which influence the visual acuity in tAMD
and PCV cases differently. Although the mean baseline
GLD was significantly greater in the PCV group than in
the tAMD group in the present study, the results of the
multivariate logistic regression analysis revealed that the
lesion phenotype (tAMD or PCV) was the independent
prognostic factor for the 12 month visual outcome after
IVR. Moreover, the ANOVA indicated a significantly
better visual prognosis in tAMD than PCV treated by
IVR over a 12 month follow-up period. The logistic
regression analysis also determined higher BMI as an in-
dependent beneficial factor for visual improvement after
IVR, although the reason was unknown. A recent study
demonstrated that circulating VEGF-A levels were
strongly correlated with BMI [30] and the patients with
higher baseline VEGF-A levels might be more suscep-
tible to ranibizumab treatment. In the present study, themean number of IVR injections was 4.1 (3.9 in tAMD
group, 4.2 in PCV group), which was compatible with
previous reports [24,31]. However, these reports and our
results did not achieve an equivalent improvement in
BCVA when compared to the ANCHOR or MARINA
study. This suggests that some patients in our study
might have been under-treated by the PRN protocol, as
discussed in the SUSTAIN study [23]. In addition, there
might be an extended interval between a decision of
retreatment and a performance of retreatment in our
study. Delay of treatment might have a potential risk of
irreversible VA deterioration [32], and may be associated
with a lower number of retreatments with IVR.
The effects of IVR against PCV are currently conten-
tious, and no consensus has been made to date. Some
studies reported that the polypoidal lesions of PCV were
barely resolved by anti-VEGF monotherapy, which might
explain the limited efficacy of IVR against PCV [9,10].
However, other reports suggested that the disappearance
of the polypoidal lesions occurred at a high rate in PCV
cases with anti-VEGF monotherapy [26,33,34]. Although
the PCV cases showed a modest improvement in their
mean BCVA over 12 months in the present study, our
results demonstrated that IVR rescued the vision of
PCV patients, since we previously reported that the
mean BCVA of PCV cases had deteriorated significantly
by 12 months following their natural course [35]. In
addition, some recent studies reported a significant im-
provement of the visual acuity of PCV patients using
IVR [26,33,34]. A recent report demonstrated that sev-
eral pretreatment factors of PCV influenced the out-
come of IVR [36], which might cause the inconsistent
results of those studies regarding the effect of IVR on
PCV. The worse baseline BCVA in the tAMD group
than the PCV group (though not significant) might be
associated with the Ceiling effects on the BCVA change
after the treatment in the present study [37]. Further
studies with prospective nature using larger and better
matched populations will be required to make a robust
conclusion. The lack of data about the duration of symp-
toms that may influence the outcome of the treatment is
another limitation of the present study.
It is interesting that several reports have shown differ-
ent outcomes for PDT between tAMD and PCV patients
[38,39]. In those reports, significantly better visual out-
comes were demonstrated for PCV than tAMD. Re-
cently, a multi-center study was conducted to compare
the effects of PDT and IVR in patients with PCV, and
reported that both therapies as well as their combination
(PDT + IVR) resulted in improvements of the patients’
visual acuity at 6 months post-treatment [40]. In addition,
PDT monotherapy and combination therapy achieved a
significantly higher proportion of patients with complete
polyp regression at 6 months than IVR monotherapy.
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http://www.biomedcentral.com/1471-2415/13/10Hence, it is important to evaluate the long-term results of
IVR with a large number of subjects to determine the
efficacy and durability of this therapy, particularly in PCV
patients. Taken together, further investigation will be
needed to determine the correct indications for IVR for
exudative AMD.
Conclusion
In conclusion, IVR is an effective therapy to improve the
vision of Japanese AMD patients, although this effect
might be greater in tAMD patients than in PCV
patients.
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